Update on device technologies for monitoring heart failure

Bharat Singh, Stuart D. Russell, Alan Cheng

Research output: Contribution to journalArticle

Abstract

Congestive heart failure (CHF) affects more than 5 million people in the United States and is one of the most common reasons for recurrent hospitalizations. Since the majority of admissions related to CHF are secondary to progressively worsening congestion, many clinicians are quick to initiate aggressive diuresis once early signs of impending heart failure develop. These signs are based in large measure on patient-reported symptoms. Unfortunately, recent trials have shown that traditional ambulatory monitoring of heart failure using patient symptoms or body weight do not reduce episodes of decompensated heart failure requiring hospitalization. This has led to great interest in developing monitoring systems that can detect impending episodes of CHF even prior to the development of symptoms. Some of the these systems utilize existing implantable cardioverter defibrillators and cardiac resynchronization therapy devices to monitor electrophysiologic parameters including the presence of ventricular arrhythmias, heart rate variability and even transthoracic impedances. Other more recent developments have focused on more invasive hemodynamic monitoring systems that can measure pressures in the right ventricle, pulmonary arteries and the left atrium. The data on the utility of such systems is limited but encouraging. While none of these systems are currently FDA approved, they have been applied in a number of clinical trials. This paper highlights the currently available monitoring systems for heart failure and reviews the evidence supporting its use.

Original languageEnglish (US)
Pages (from-to)536-549
Number of pages14
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume14
Issue number5
DOIs
StatePublished - Oct 2012

Fingerprint

Heart Failure
Technology
Equipment and Supplies
Hospitalization
Cardiac Resynchronization Therapy Devices
Impedance Cardiography
Ambulatory Monitoring
Implantable Defibrillators
Diuresis
Heart Atria
Pulmonary Artery
Heart Ventricles
Cardiac Arrhythmias
Heart Rate
Hemodynamics
Body Weight
Clinical Trials
Pressure

Keywords

  • Devices
  • Heart failure
  • Monitoring
  • Review

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Update on device technologies for monitoring heart failure. / Singh, Bharat; Russell, Stuart D.; Cheng, Alan.

In: Current Treatment Options in Cardiovascular Medicine, Vol. 14, No. 5, 10.2012, p. 536-549.

Research output: Contribution to journalArticle

Singh, Bharat ; Russell, Stuart D. ; Cheng, Alan. / Update on device technologies for monitoring heart failure. In: Current Treatment Options in Cardiovascular Medicine. 2012 ; Vol. 14, No. 5. pp. 536-549.
@article{c6ca3f40fa2444d88ae03b9421beeb19,
title = "Update on device technologies for monitoring heart failure",
abstract = "Congestive heart failure (CHF) affects more than 5 million people in the United States and is one of the most common reasons for recurrent hospitalizations. Since the majority of admissions related to CHF are secondary to progressively worsening congestion, many clinicians are quick to initiate aggressive diuresis once early signs of impending heart failure develop. These signs are based in large measure on patient-reported symptoms. Unfortunately, recent trials have shown that traditional ambulatory monitoring of heart failure using patient symptoms or body weight do not reduce episodes of decompensated heart failure requiring hospitalization. This has led to great interest in developing monitoring systems that can detect impending episodes of CHF even prior to the development of symptoms. Some of the these systems utilize existing implantable cardioverter defibrillators and cardiac resynchronization therapy devices to monitor electrophysiologic parameters including the presence of ventricular arrhythmias, heart rate variability and even transthoracic impedances. Other more recent developments have focused on more invasive hemodynamic monitoring systems that can measure pressures in the right ventricle, pulmonary arteries and the left atrium. The data on the utility of such systems is limited but encouraging. While none of these systems are currently FDA approved, they have been applied in a number of clinical trials. This paper highlights the currently available monitoring systems for heart failure and reviews the evidence supporting its use.",
keywords = "Devices, Heart failure, Monitoring, Review",
author = "Bharat Singh and Russell, {Stuart D.} and Alan Cheng",
year = "2012",
month = "10",
doi = "10.1007/s11936-012-0192-7",
language = "English (US)",
volume = "14",
pages = "536--549",
journal = "Current Treatment Options in Cardiovascular Medicine",
issn = "1092-8464",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Update on device technologies for monitoring heart failure

AU - Singh, Bharat

AU - Russell, Stuart D.

AU - Cheng, Alan

PY - 2012/10

Y1 - 2012/10

N2 - Congestive heart failure (CHF) affects more than 5 million people in the United States and is one of the most common reasons for recurrent hospitalizations. Since the majority of admissions related to CHF are secondary to progressively worsening congestion, many clinicians are quick to initiate aggressive diuresis once early signs of impending heart failure develop. These signs are based in large measure on patient-reported symptoms. Unfortunately, recent trials have shown that traditional ambulatory monitoring of heart failure using patient symptoms or body weight do not reduce episodes of decompensated heart failure requiring hospitalization. This has led to great interest in developing monitoring systems that can detect impending episodes of CHF even prior to the development of symptoms. Some of the these systems utilize existing implantable cardioverter defibrillators and cardiac resynchronization therapy devices to monitor electrophysiologic parameters including the presence of ventricular arrhythmias, heart rate variability and even transthoracic impedances. Other more recent developments have focused on more invasive hemodynamic monitoring systems that can measure pressures in the right ventricle, pulmonary arteries and the left atrium. The data on the utility of such systems is limited but encouraging. While none of these systems are currently FDA approved, they have been applied in a number of clinical trials. This paper highlights the currently available monitoring systems for heart failure and reviews the evidence supporting its use.

AB - Congestive heart failure (CHF) affects more than 5 million people in the United States and is one of the most common reasons for recurrent hospitalizations. Since the majority of admissions related to CHF are secondary to progressively worsening congestion, many clinicians are quick to initiate aggressive diuresis once early signs of impending heart failure develop. These signs are based in large measure on patient-reported symptoms. Unfortunately, recent trials have shown that traditional ambulatory monitoring of heart failure using patient symptoms or body weight do not reduce episodes of decompensated heart failure requiring hospitalization. This has led to great interest in developing monitoring systems that can detect impending episodes of CHF even prior to the development of symptoms. Some of the these systems utilize existing implantable cardioverter defibrillators and cardiac resynchronization therapy devices to monitor electrophysiologic parameters including the presence of ventricular arrhythmias, heart rate variability and even transthoracic impedances. Other more recent developments have focused on more invasive hemodynamic monitoring systems that can measure pressures in the right ventricle, pulmonary arteries and the left atrium. The data on the utility of such systems is limited but encouraging. While none of these systems are currently FDA approved, they have been applied in a number of clinical trials. This paper highlights the currently available monitoring systems for heart failure and reviews the evidence supporting its use.

KW - Devices

KW - Heart failure

KW - Monitoring

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=84870297287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870297287&partnerID=8YFLogxK

U2 - 10.1007/s11936-012-0192-7

DO - 10.1007/s11936-012-0192-7

M3 - Article

C2 - 22911315

AN - SCOPUS:84870297287

VL - 14

SP - 536

EP - 549

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

SN - 1092-8464

IS - 5

ER -